| Niacin as potential treatment for dyslipidemia and hyperphosphatemia associated with chronic renal failure: the need for clinical trials. | |
| | |
MedLine Citation:
|
PMID: 20486851 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Niacin has profound and unique effects on lipid metabolism. In addition to increasing high-density lipoprotein cholesterol, it is also known to decrease total cholesterol, low-density lipoprotein cholesterol, and triglyceride. Interestingly, the plasma concentration of lipoprotein(a) [Lp(a)], which has been suggested to play a role as an independent risk factor for coronary heart disease, is also decreased by niacin. Therefore, it is not surprising that in the literature it was given unique description as broad-spectrum lipid drug. Its impact is referred to as desirable normalization of a range of cardiovascular risk factors. However, its clinical use is limited due to harmless but unpleasant unique side effect of cutaneous flushing. Interestingly, recent experimental and clinical studies suggest the potential benefit of niacin as a treatment of dyslipidemia and high plasma phosphate associated with chronic kidney disease (CKD). Both dyslipidemia and high serum phosphate levels are shown to be associated with higher cardiovascular mortality. Furthermore, niacin administration improves renal tissue lipid metabolism, renal function and structure, hypertension, proteinuria, and histological tubulointerstitial injury. Further studies are required before the use of niacin for the treatment of both dyslipidemia and hyperphosphatemia with CKD advocated. |
| | |
Authors:
|
Mohamed H Ahmed |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Renal failure Volume: 32 ISSN: 1525-6049 ISO Abbreviation: Ren Fail Publication Date: 2010 Jun |
Date Detail:
|
Created Date: 2010-05-21 Completed Date: 2010-09-10 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8701128 Medline TA: Ren Fail Country: England |
Other Details:
|
Languages: eng Pagination: 642-6 Citation Subset: IM |
Affiliation:
|
Chemical Pathology Department, Southampton University Hospitals NHS Trust, Southampton SO16 6YD, UK. elziber@yahoo.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antilipemic Agents
/
therapeutic use* Clinical Trials as Topic Dyslipidemias / drug therapy*, etiology Humans Hyperphosphatemia / drug therapy*, etiology Kidney Failure, Chronic / complications* Niacin / therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
0/Antilipemic Agents; 59-67-6/Niacin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: An unusual cause of focal segmental glomerulosclerosis: psoriasis vulgaris.
Next Document: Corrigendum.